ENDLESS

Endless Biotech

Cultivating the Future of Agriculture

Forward-Looking Statements

These offering materials may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company's management. When used in the offering materials, the words "estimate," "project," "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. These statements reflect management's current views with respect to future events and are subject to risks and uncertainties that could cause the company's actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

Please note investors in this offering will be clients of the issuer and not Dalmore Group, LLC ("Dalmore"), a registered broker-dealer and member FINRA/SIPC. Dalmore's role in the transaction is to facilitate back-office and regulatory functions related to the Regulation A transaction, and acts only as the broker/dealer of record for the offering listed. Dalmore is not providing investment advice or recommendations, or legal or tax advice.

This Reg A investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. All investors should make their own determination, with the assistance of their own financial or other advisors, as to whether or not to make any investment, based on their own independent evaluation, analysis, and circumstances.

No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement filed by the company with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification. An indication of interest involves no obligation or commitment of any kind. An offering statement regarding this offering has been filed with the SEC. You may obtain a copy of the preliminary offering circular that is part of that offering statement. [Form 1-A filing with SEC]

ENDLESS

Industry Problem

Inconsistency, contamination, scalability, and preservation issues limit growth



INCONSISTENT QUALITY

Traditional methods produce variable plants, risking product reliability.



DISEASE AND PEST RISKS

Contamination reduces yields and drives up costs.

LIMITED SCALABILITY

Current propagation techniques can’t keep pace with market demands.

GENETIC VULNERABILITY

Rare strains are lost due to outdated preservation.

ENDLESS

Solution

Precision, preservation, data, and scalability redefine cannabis cultivation



TISSUE CULTURE TECHNOLOGY

Produces consistent, disease-free plants at scale with unmatched precision.

PRESERVING GENETICS

Protects rare and valuable strains through cutting-edge preservation techniques.

DATA-DRIVEN INNOVATION

Utilizes robotics, AI, and molecular diagnostics for optimized growth processes.

SCALABLE PRODUCTION

Delivers millions of identical, high-quality clones reliably and efficiently.

ENDLESS

Tissue Culture Technology

Revolutionizing Cannabis Cultivation Through Tissue Culture

At Endless Biotech, precision isn't a goal—it's the standard. Tissue culture has transformed how cannabis is cultivated, ensuring every plant thrives with unparalleled consistency and care.

Tissue culture isn't just about growing plants—it's about cultivating innovation, sustainability, and the future of agriculture.

HEALTHIER PLANTS

Disease and pest-free plants ensure robust, thriving crops.

CONSISTENT QUALITY

Plants are engineered as identical clones, ensuring consistent potency and quality.

ACCELERATED GROWTH

Faster-growing plants lead to quicker harvests and higher efficiency.

EFFICIENT SPACE USE

Efficient production maximizes space while reducing costs.

ENDLESS

Genetic Preservation

Safeguarding the Legacy of Cannabis Cultivation

Preserving cannabis genetics is no longer a challenge—it's an opportunity. At Endless Biotech, we ensure that cultivators never lose the unique traits that define their success.

Endless Biotech's genetic preservation secures the legacy of cannabis cultivation, paving the way for innovation and excellence for generations to come.

COMPREHENSIVE STRAIN LIBRARY

Ensures consistency with a reliable source of genetics.

ADVANCED TISSUE CULTURE TECHNIQUES

Preserves purity and original traits in a sterile environment.

LONG-TERM VIABILITY

Secures stability for future cultivation and breeding.

PATHOGEN-FREE PRESERVATION

Eliminates disease and pests for healthier plants.

ENDLESS

Data-Driven Innovation

Smart Cultivation Through Data

Our data-driven approach transforms every stage of the process, from predicting growth patterns to optimizing plant health and yield. With advanced robotics and adaptive AI, Endless Biotech leads the charge in precision cultivation.

Endless Biotech's innovation paves the way for an automated, scalable future where cutting-edge technology meets sustainable growth—ensuring unmatched success for our partners.

AI-POWERED PRECISION

Adaptive AI ensures consistent, optimal results across cultivation cycles.

ROBOTICS INTEGRATION

Advanced robotics streamline labor-intensive tasks for greater efficiency.

PREDICTIVE ANALYTICS

Insights forecast growth patterns and optimize plant health and yields.

ENHANCED SCALABILITY

Automated systems enable rapid growth without compromising quality.

ENDLESS

Endless Biotech's Scalability Breakthrough



7 million identical plants...

Endless Biotech is building toward the ability to scale from a single tissue culture to over 7 million identical plants **within 120 days.**

ENDLESS

...and we can do this for every single customer!

Expanding our Verticals

While Endless Biotech's tissue culture expertise currently powers cannabis cultivation at scale, we are actively researching and developing cutting-edge solutions for a broader agricultural future. Our meticulous approach to plant genetics transcends the cannabis sector, focusing on four key areas:

HORTICULTURE

Advanced horticultural genetics ensuring improved yield, resilience, and consistency.

TREE SPECIES

Reliable, genetically optimized tree varieties for sustainable landscaping and agricultural applications.

FLORICULTURE

Specialized floriculture genetics for vibrant and resilient blooms.

CANNABIS

Meticulously cultivated cannabis genetics engineered for optimal growth and unmatched potency.

Expanding Beyond Cannabis

Horticulture

Advanced horticultural genetics aimed at improving yield, resilience, and consistency in everyday staple crops.

Future-forward R&D to enhance the reliability of produce for growers worldwide.

Fruits/Berries

- Strawberry
- Banana
- Blueberry
- Fig

Vegetables/Edibles

- Potato
- Sweet Potato
- Corn

Expanding Beyond Cannabis

Tree Species

Reliable, genetically curated tree varieties for sustainable landscaping and large-scale agricultural applications.

Early-stage research targeting higher survival rates and uniform growth patterns in commercial forestry.

- Paulownia (Empress tree)
- Ficus



Expanding Beyond Cannabis

Floriculture

Specialized genetics for vibrant, resilient blooms, including refined Orchids and robust Chrysanthemums.

Leveraging tissue culture to unlock unique ornamental plant varieties for florists and horticultural enthusiasts.

- Mums
- Carnation
- Gerbera
- Orchids

Currently in full-scale production

Cannabis

Currently in full-scale production with cultivated Indica, Sativa, and Hybrid varieties—engineered for optimal growth and improved output.

Continual refinement of tissue culture protocols to maintain consistency and maximize yields.

- Indica
- Sativa
- Hybrid



Where We Are Today

Cannabis is our fully operational initial production sector, generating revenue and showing efficacy of our tissue culture model at a commercial scale.

Horticulture, **Trees**, and **Floriculture** remain in R&D, leveraging the same high-precision tissue culture techniques to pave the way for future expansions into global agriculture.

Why It Matters

By diversifying our research and capabilities, Endless Biotech aims to position itself as a leading biotech innovator, not just in cannabis but in agriculture at large.

This multi-pronged approach safeguards us against market fluctuations in any one sector and sets the stage for significant long-term growth.

ENDLESS

Market Opportunity

A Booming Global Cannabis Market

228M

**Cannabis consumers worldwide.

76+

***Countries have legalized some form of medical cannabis.

$444B

*Projected global market size by 2030.

CAGR 34%

*Compound annual growth rate through 2030.

Sources: * Fortune Business Insights ** United Nations *** Wikipedia

ENDLESS

Key Performance Indicators

Endless Biotech by the Numbers

$2.2M

Traditional clones revenue.

$20M

Turned away in orders.

230k

Clones sold in a small Oklahoma market.

$120M

Global leads and counting.

ENDLESS

Scaling for the Future

4 Phases of Growth

WE ARE HERE

PHASE I: PROOF OF CONCEPT

Status

Complete

Objective

Validate cloning feasibility for the cannabis industry.

Outcome

Established high-quality clone production and market demand.

PHASE II: INITIAL EXPANSION

Status

Complete

Objective

Remodel Building I for **40,000+ clones**/month.

Outcome

Optimized space, workflows, and production capacity.

PHASE III: SCALING UP

Status

In Progress

Objective

Expand Building I to scale capacity to **±1M clones**/month.

Outcome

Architectural plans and permitting in progress.

PHASE IV: GLOBAL GROWTH

Status

Planned

Objective

Construct 40k sq. ft. Building II for **5M clones**/month.

Outcome

State-of-the-art facilities for global distribution & efficiency.

ENDLESS

Phase I: Proof of Concept

Established high-quality clone production and market demand.

Complete

ENDLESS

Phase II: Initial Expansion

Optimized space, workflows, and production capacity.

Complete

ENDLESS

Phase III: Scaling Up

Expand Building I to scale capacity to ±1M clones/month.

In Progress



ENDLESS

Phase IV: Global Growth

Building the foundation for global scalability and precision.

The 40,000 sq. ft. facility will increase capacity to over 5M clones/month, featuring cutting-edge labs and climate-controlled systems.

Integrating robotics and AI to streamline production, enhance precision, and cut costs while ensuring consistent quality.

The full campus will drive international expansion, positioning Endless Biotech as a leader in scalable agriculture.

Play

ENDLESS

Phase III: Scaling Up – Completed (Q4 2025)

Revenue Potential

DISEASE IDENTIFICATION

GENETIC PRESERVATION

TISSUE CULTURE

$108M

Targeted annual revenue from ±1M clones/month, leveraging **multiple plant species.**

EDUCATION

DNA BARCODING

CRISPR

BREEDING

ROBOTICS

Disclaimer: This figure represents a targeted projection based on internal estimates. Actual results may vary, and there is no guarantee the company will reach this level of revenue or clone production capacity.

ENDLESS

Phase IV: Global Growth – Completed

Revenue Potential

DISEASE IDENTIFICATION

GENETIC PRESERVATION

TISSUE CULTURE

$600M

Targeted annual revenue from 5M clones/month, leveraging **multiple plant species.**

EDUCATION

DNA BARCODING

CRISPR

BREEDING

ROBOTICS

Disclaimer: This figure represents a targeted projection based on internal estimates. Actual results may vary, and there is no guarantee the company will reach this level of revenue or clone production capacity.

Trusted by Industry Leaders

“

Endless Biotech’s facility is top-notch and impeccably clean. Their passionate and professional team operates with cutting-edge efficiency, delivering exceptional, science-backed, data-driven results. If you’re looking for the future of cannabis cultivation, Endless is the answer.

John Pratt, Regional Sales, Quest

“

Endless Biotech is redefining Crop Steering Methodology with phenomenal yields and unmatched product quality. They’re making waves locally, nationally, and internationally—watching their growth in the coming years will be exciting!

Andrew Tharp, Regional Sales, Grodan

“

Endless Biotech has transformed Tulsa into a hub for cutting-edge cannabis cultivation. With a state-of-the-art facility and a team driven by science and passion, they’re setting new industry standards for clean, high-quality genetics. A force to watch in the cannabis industry!

Mike Howard, Chief Horticulture Officer, FoHSE

FOHSE

PIPP HORTICULTURE

QUEST

Grodan

ATHENA

AROYA

ENDLESS

Meet the Team

TRAVIS DAHM

Chief Executive Officer

Driving visionary leadership with a focus on scalability and innovation in agriculture.

BRAZ VAIDYA

Chief Scientist

Spearheading tissue culture advancements with 15+ years of research experience.

GARY HOLLAND

Chief Innovation Officer

Combining engineering expertise and AI innovation to optimize operations and drive scalable solutions.

COURTNEY BRIDGES

Head of Analytics

Blending biology and data science to ensure optimal plant health and operational efficiency.

ENDLESS

Vertical	Addressable TAM	Growth TAM	Target Growth Capture	Projected Revenue
Cannabis [1]	$174B	$65B	2%	~$1.3B
Industrial Hemp [2]	$48B	$10B	2%	~$200M
Ornamentals [3]	$127B	$54B	2%	~$1.1B
India Germination [4]	–	$30B+	1%	~$300M
Education [5]	$46B	$4B	5%	~$200M

[1] New Frontier Data, BDSA, Statista, and Grand View Research
[2] Markets and Markets, Brightfield Group, and USDA projections
[3] IBIS World, USDA Floriculture Reports, and Statista
[4] USDA Foreign Ag Service, India's Ministry of Agriculture, IMARC, and McKinsey India Agri Reports
[5] HolonIQ, Global Market Insights, and EdTech Market Reports

ENDLESS

- Average EBITDA Margin: 25%
- Average OpEx: ~49% of Revenue
- Average Headcount CAGR: ~+20% YoY

Year 1

Revenue
$558M

EBITDA
$139.5M

OpEx
$271.8M

180 people

Year 2

Revenue
$697.5M

EBITDA
$174.4M

OpEx
$339.8M

242 people

Year 3

Revenue
$871.9M

EBITDA
$223.4M

OpEx
$424.7M

308 people

ENDLESS

Funding Breakdown

Capital Allocation Overview

To meet the growing global demand for scalable, precision-grown plant systems, Endless Biotech is allocating $15 million across five strategic categories.

This funding will support infrastructure expansion, innovation, acquisitions, and operational excellence—positioning Endless as a global leader in tissue culture and biotech propagation.

Investor Reporting, Legal & Offering Costs

$500k

Offering compliance, audits, legal, IR communications

Working Capital & Staffing

$1.25M

General operations, recruitment, software, contingency

Plant Molecular Biology & Gene Editing Lab

$2.5M

Instrumentation, CRISPR/NGS systems, reagents, and 10-person scientific team

Strategic Acquisitions

$5M

IP, competitor labs, regional infrastructure or distressed asset purchases

Tissue Culture Production Scale-Up

$5.25M

Scaling production to 1M clones per month through investment in equipment, automation, personnel, bioreactors, and essential consumables

$15M
Total

ENDLESS

Join the Future of Agriculture

Your investment empowers us to complete key phases in our growth strategy, paving the way for our planned Nasdaq listing by 2028.

- Targeted Laboratory Expansion
- Develop Operations
- Scale Production Capacity
- Strategic Hires

In no way limiting the forgoing, any reference to any objective, goal, intention, or plan of Endless Corporation becoming, emulating, or operating in a similar manner as Fortune 100 and 500 companies is not a guarantee that it will be able to do so, or will not elect to do otherwise, now or in the future. In addition, while this website may reference aspirations of Endless Corporation for a NASDAQ IPO, it is still formulating and has not yet decided on or yet implemented a plan to achieve such result. Future results are not guaranteed, nor is how, the capability to achieve such results, and no investment decision should be based upon the potential of a future NASDAQ IPO, or any other potential future event discussed herein.

Visit: investendless.com